Nanobiotix S.A. American Depositary Shares NBTX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:39:26.122Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:33:35.813772052Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:39:25.755020+00:00
Nanobiotix S.A. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.02 | 291.9% | 31.2% | |||
| 25Δ | 26.21 | 245.7% | 24.7% | |||
| 30Δ | 43.61 | 263.5% | 43.2% | 27.97 | 211.8% | 19.6% |
| 35Δ | 38.99 | 218.1% | 29.0% | 29.73 | 178.0% | 14.6% |
| 40Δ | 36.38 | 191.0% | 21.3% | 30.64 | 163.8% | 12.4% |
| 45Δ | 34.58 | 168.9% | 16.0% | 31.39 | 153.0% | 10.7% |
| 50Δ | 33.69 | 152.1% | 13.4% | 32.14 | 142.3% | 9.1% |
| 55Δ | 32.80 | 135.4% | 10.8% | 32.90 | 131.6% | 7.4% |
| 60Δ | 31.91 | 118.7% | 8.2% | 33.65 | 120.9% | 5.8% |
| 65Δ | 31.01 | 101.9% | 5.6% | 34.40 | 110.1% | 4.1% |
| 70Δ | 30.12 | 85.2% | 3.0% | 35.40 | 104.7% | 2.7% |
| 75Δ | 28.67 | 101.7% | 2.5% | 37.38 | 119.9% | 2.4% |
| 80Δ | 27.13 | 123.6% | 2.2% | 39.37 | 135.2% | 2.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.02
- IV
- 291.9%
- B/E move
- 31.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 26.21
- IV
- 245.7%
- B/E move
- 24.7%
30Δ
- Pseudo strike
- 43.61
- IV
- 263.5%
- B/E move
- 43.2%
- Pseudo strike
- 27.97
- IV
- 211.8%
- B/E move
- 19.6%
35Δ
- Pseudo strike
- 38.99
- IV
- 218.1%
- B/E move
- 29.0%
- Pseudo strike
- 29.73
- IV
- 178.0%
- B/E move
- 14.6%
40Δ
- Pseudo strike
- 36.38
- IV
- 191.0%
- B/E move
- 21.3%
- Pseudo strike
- 30.64
- IV
- 163.8%
- B/E move
- 12.4%
45Δ
- Pseudo strike
- 34.58
- IV
- 168.9%
- B/E move
- 16.0%
- Pseudo strike
- 31.39
- IV
- 153.0%
- B/E move
- 10.7%
50Δ
- Pseudo strike
- 33.69
- IV
- 152.1%
- B/E move
- 13.4%
- Pseudo strike
- 32.14
- IV
- 142.3%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- 32.80
- IV
- 135.4%
- B/E move
- 10.8%
- Pseudo strike
- 32.90
- IV
- 131.6%
- B/E move
- 7.4%
60Δ
- Pseudo strike
- 31.91
- IV
- 118.7%
- B/E move
- 8.2%
- Pseudo strike
- 33.65
- IV
- 120.9%
- B/E move
- 5.8%
65Δ
- Pseudo strike
- 31.01
- IV
- 101.9%
- B/E move
- 5.6%
- Pseudo strike
- 34.40
- IV
- 110.1%
- B/E move
- 4.1%
70Δ
- Pseudo strike
- 30.12
- IV
- 85.2%
- B/E move
- 3.0%
- Pseudo strike
- 35.40
- IV
- 104.7%
- B/E move
- 2.7%
75Δ
- Pseudo strike
- 28.67
- IV
- 101.7%
- B/E move
- 2.5%
- Pseudo strike
- 37.38
- IV
- 119.9%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 27.13
- IV
- 123.6%
- B/E move
- 2.2%
- Pseudo strike
- 39.37
- IV
- 135.2%
- B/E move
- 2.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 82.45% | |
| 74.01% | |
| 83.99% | |
| 84.40% | |
| 86.00% |
Biotechnology
NGNE
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical…
More →NKTR
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad,…
More →NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco,…
More →NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and…
More →NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and…
More →NRXP
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders…
More →